Voyager Therapeutics, Inc. Q3 FY2023 earnings call

Al Sandrock discussed Voyager's TRACER capsid discovery platform for CNS gene therapy delivery, with novel capsids showing robust CNS tropism. The pipeline includes two wholly owned and two partnered CNS programs, with the anti-tau antibody program anticipating an IND filing in the first half of 2024 and the SOD1 program on track for development candidate selection by year-end. Voyager secured over $200 million in non-dilutive partnering revenue in 2023, has 11 partnered programs, and had ~$253 million in cash as of Q3 2023. Milestones achieved include initiating GLP toxicology studies for VY-TAU01, selecting a development candidate for the anti-tau antibody, and launching early-stage gene therapy programs. Future plans involve multiple IND filings across wholly-owned and collaborative programs and advancing neurogenetic medicines.

No specific product segment financial performance details provided in the transcript.

Cash runway into mid-2025 based on existing cash, reimbursements, and interest income. Expect IND filings in the first half of 2024 for the anti-tau antibody and in mid-2025 for the SOD1 program. Potential for milestone payments and human proof of concept for TRACER capsids. Ongoing discussions with partners regarding collaborations and licensing.

Forward-looking statements subject to uncertainties and risks causing actual results to differ. Risks detailed in SEC filings, including market, regulatory, and clinical trial risks.

Q: As you consider nominating your genetic medicine, what are some considerations as you decide which route to go and which strategies to use?

A: Dr. Al Sandrock and Dr. Todd Carter discussed that gene therapy is the core technology, but they are exploring Receptor X for shuttling other modalities, viewing it as a toolbox with multiple modalities for different diseases.

Q: In your cash runway guidance into mid-2025, what's included in that assumption?

A: Pete Pfreundschuh explained it's based on cash on balance sheet, reimbursements, and interest income, not including potential milestones from partnered programs.

Q: When might preclinical studies for the shuttle program read out?

A: Dr. Todd Carter stated the shuttle program is in early stages with no specific timeline yet.

Q: How do you plan to finance clinical trials next year?

A: Pete Pfreundschuh discussed funding wholly-owned programs within cash guidance, with partner programs' milestones not affecting balance sheet funding.

Q: What are considerations for patient selection in tau program trials?

A: Dr. Al Sandrock mentioned using tau PET imaging and early-stage Alzheimer's disease patients, mirroring BIIB080's approach.

Q: At what stage is Receptor X efforts for potential partnerships?

A: Dr. Al Sandrock said they need in vivo evidence of shuttling macro molecules across BBB with desired effect for partnership discussions.